Omvoh Durable UC Data Adds Pipeline Diversification but Does Not Alter Core GLP-1 Thesis

What happened

Lilly announced long-term data from the LUCENT-3 study showing that 63.5% of patients who achieved disease clearance with Omvoh (mirikizumab-mrkz) maintained it through four years, positioning Omvoh as the first IL-23p19 with durable remission in ulcerative colitis. This positive data adds to Lilly's pipeline strength beyond the GLP-1 franchise, highlighting potential in immunology. However, the DeepValue Master Report emphasizes that LLY's valuation and near-term outlook remain dominated by GLP-1 dynamics: price compression (-13% consolidated in Q1'26), one-time rebate adjustments, and the scaling of oral Foundayo. The Omvoh data, while clinically meaningful, does not materially change the revenue or earnings trajectory over the next 12 months, as the drug is still building market share in a competitive IBD space. Investors should view this as a positive but incremental signal that does not offset the pricing risks central to the current WAIT rating.

Implication

The Omvoh data bolsters Lilly's immunology pipeline, demonstrating long-term efficacy in UC that could drive modest revenue growth and diversify the product mix. However, the core investment thesis remains tied to GLP-1 trajectory: volume growth must outpace continued net price erosion, with Q1'26 showing price -13% and reliance on one-time adjustments. Foundayo's uptake and Medicare Bridge effects are the key 6-12 month catalysts, not Omvoh. The sustainable competitive advantage in incretins is what supports the premium valuation, and pricing pressure remains the primary risk. The Omvoh data does not alter the WAIT rating or the attractive entry near $850.

Thesis delta

The Omvoh four-year durability data is a positive pipeline data point that marginally reduces the risk of over-concentration on GLP-1s, but does not shift the investment thesis. The GLP-1 pricing headwinds (-13% in Q1) and the need for Foundayo to drive incremental new-to-class starts remain the dominant factors. The thesis still hinges on price stabilization and volume growth, not expanded pipeline optionality.